High materiality8/10
Morgan Stanley Starts Enliven Therapeutics (ELVN) at Overweight
Why it may matterVerify against the original reporting
Upside potential supported by target vs current price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst Morgan Stanley initiates ELVN with an Overweight rating and targets a price of 70; current price is 46.21.
- Target 70 vs price 46.21; bullish setup.
Key facts
- 01
Target: $70
- 02
Posted price: $46.21
- 03
Analyst firm: Morgan Stanley
- 04
Analyst: Sean Laaman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.